; odds ratio (OR) 5 1.29). The association was stronger in younger, leaner people with type 2 diabetes, and replicated in independent samples (P 5 1.1 3 10
24
; OR 5 1.20). The risk haplotype carries four amino acid substitutions, all in SLC16A11; it is present at 50% frequency in Native American samples and 10% in east Asian, but is rare in European and African samples. Analysis of an archaic genome sequence indicated that the risk haplotype introgressed into modern humans via admixture with Neanderthals. The SLC16A11 messenger RNA is expressed in liver, and V5-tagged SLC16A11 protein localizes to the endoplasmic reticulum. Expression of SLC16A11 in heterologous cells alters lipid metabolism, most notably causing an increase in intracellular triacylglycerol levels. Despite type 2 diabetes having been well studied by genomewide association studies in other populations, analysis in Mexican and Latin American individuals identified SLC16A11 as a novel candidate gene for type 2 diabetes with a possible role in triacylglycerol metabolism.
The Slim Initiative in Genomic Medicine for the Americas (SIGMA) Type 2 Diabetes Consortium set out to characterize the genetic basis of type 2 diabetes in Mexican and other Latin American populations, where the prevalence is roughly twice that of US non-Hispanic whites 5 (see also http://www.cdc.gov/diabetes/pubs/factsheet11.htm). This report considers 3,848 type 2 diabetes cases and 4,366 controls (Table 1) genotyped using the Illumina OMNI 2.5 array that were unrelated to other samples, and that fall on a cline of Native American and European ancestry 6 (Extended Data Fig. 1 ). Association analysis included 9.2 million variants that were imputed 7, 8 from the 1000 Genomes Project Phase I release 9 based on 1.38 million SNPs directly genotyped at high quality with minor allele frequency (MAF) .1%.
The association of SNP genotype with type 2 diabetes was evaluated using LTSOFT 10 , a method that increases power by jointly modelling case-control status with non-genetic risk factors. Our analysis used body mass index (BMI) and age to construct liability scores and also included adjustment for sex and ancestry via principal components 6 . The quantile-quantile (QQ) plot is well calibrated under the null (l GC 5 1.05; Fig. 1a, red) , indicating adequate control for confounders, with substantial excess signal at P , 10
. We first examined SNPs previously reported to be associated to risk of type 2 diabetes. Two such variants reached genome-wide significance: TCF7L2 (rs7903146; P 5 2.5 3 10
217
; OR 5 1.41 (95% confidence interval 1.30-1.53)) and KCNQ1 (rs2237897; P 5 4.9 3 10
216
; OR 5 0.74 (0.69-0.80)) (Extended Data Figs 2, 3a), with effect sizes and frequencies consistent with previous studies 3, 4, 11 . At KCNQ1, we identified a signal 3 of association that shows limited linkage disequilibrium both to rs2237897 (r 2 5 0.056) and to rs231362 (r 2 5 0.028) (previously seen in Europeans 11 ), suggesting a third allele at this locus (rs139647931; after conditioning, P 5 5. More generally, of SNPs previously associated with type 2 diabetes at genome-wide significance, 56 of 68 are directionally consistent with the initial report (P 5 3.1 3 10
28
; Supplementary Table 1) . Nonetheless, a QQ plot excluding all SNPs within 1 megabase (Mb) of the 68 type 2 diabetes associations remains strikingly non-null (Fig. 1a, blue) .
This excess signal of association is entirely attributable to two regions of the genome: chromosome 11p15.5 and 17p13.1 (Fig. 1a, black) . The genome-wide significant association at 11p15.5 spans insulin, IGF2 and other genes (Extended Data Fig. 3a ): the SNP with the strongest association lies in the 39 untranslated region (UTR) of IGF2 and the non-coding INS-IGF2 transcript (rs11564732, P 5 2.63 10
; OR 5 0.77 (0.70-0.84); Supplementary Table 2 ). The associated SNPs are ,700 kilobases (kb) from the genome-wide significant signal in KCNQ1 (above), and analysis conditional on the two significant KCNQ1 SNPs reduced the INS-IGF2 association signal to just below genome-wide significance (P 5 7.5 3 10
27
, Extended Data Fig. 3c ). Conditioning on the two KCNQ1 SNPs and the INS-IGF2 SNP reduces the signal to background (Extended Data Fig. 3d ). Further analysis is needed to determine whether the INS-IGF2 signal is reproducible and independent of that at KCNQ1.
*Lists of participants and their affiliations appear at the end of the paper. The strongest novel association is at 17p13.1 spanning SLC16A11 and SLC16A13 (Fig. 1b) , both poorly characterized members of the monocarboxylic acid transporter family of solute carriers 12 . The strongest signal of association includes a silent mutation as well as four missense SNPs, all in SLC16A11 (Fig. 1d, e) . These five variants are (1) in strong linkage disequilibrium (r 2 $ 0.85 in 1000 Genomes samples from the Americas) and co-segregate on a single haplotype; (2) common in samples of Latin American ancestry; and (3) show equivalent levels of association to type 2 diabetes (P 5 2.4 3 10 212 to P 5 3.9 3 10
213
; OR 5 1.29 (1.20-1.38); Supplementary Tables 3-5) . Analysis conditional on any of these variants leaves no genome-wide significant signal ( Fig. 1c and Extended Data Fig. 4 ). Computational prediction with SIFT 13 (which considers each site independently) labels one of the missense SNPs (rs13342692, D127G) as damaging and the other three 'tolerated' (Supplementary Table 6 ). Individuals that carry the risk haplotype develop type 2 diabetes 2.1 years earlier (P 5 3.1 3 10
24
), and at 0.9 kg m 22 lower BMI (P 5 5.2 3 10
) than non-carriers (Extended Data Fig. 5 ). The odds ratio for the risk haplotype estimated using young cases (#45 years) was higher than in older cases (OR 5 1.48 versus 1.11; P heterogeneity 5 1.7 3 10
23
). We tested the haplotype for association with related metabolic quantitative traits in the fasting state in a subset of SIGMA participants (n 5 1,505-3,855). No associations surpass nominal significance (P , 0.05; Supplementary Table 7) . Frequencies from SIGMA samples are calculated from genotypes and represent either the entire data set (All) or only samples estimated to have $95% Native American ancestry ($95 NA, n 5 290; Supplementary Methods). Haplotypes with population frequency ,1% are not depicted. e, Predicted membrane topology of human SLC16A11 generated using TMHMM 2.0 and visualized with TeXtopo. Locations of SNPs carried by the type-2-diabetes-associated haplotype are indicated. f, Forest plot depicting odds ratio estimates at rs75493593 from the four SIGMA cohorts, the SIGMA pooled mega-analysis, the replication cohorts, replication-only meta-analysis based on inverse standard error weighting of effect sizes, and the overall meta-analysis (including all replication cohorts and the SIGMA megaanalysis). Accompanying table lists ethnicity, cohort names, estimated odds ratio (OR) and 95% confidence interval (95% CI). Replication cohorts are the Type 2 Diabetes Genetic Exploration by Next-generation sequencing in multi-Ethnic Samples (T2D-GENES), Multiethnic Cohort (MEC), and Singapore Chinese Health Study (SCHS). Further details including sample sizes are provided in Supplementary Table 8 .
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Given that large genome-wide association studies (GWAS) have been performed for type 2 diabetes in samples of European and Asian ancestry, it may seem surprising that associated variants at SLC16A11/13 were not previously identified. Using data generated by the 1000 Genomes Project and the current study, we observed that the risk haplotype (hereafter referred to as '5 SNP' haplotype) is rare or absent in samples from Europe and Africa, has intermediate frequency (,10%) in samples from east Asia, and up to ,50% frequency in samples from the Americas (Fig. 1d and Extended Data Fig. 6a) . A second haplotype carrying one of the four missense SNPs (D127G) and the synonymous variant (termed the '2 SNP' haplotype) is very common in samples from Africa but rare elsewhere, including in the Americas (Fig. 1d) . The low frequency of the 5 SNP haplotype in Africa and Europe may explain why this association was not found in previous studies.
We attempted to replicate this association in ,22,000 samples from a variety of ancestry groups. A proxy for the 5 SNP haplotype of SLC16A11 showed strong association with type 2 diabetes (P replication 5 1. Table 8 ). The association was clearly observed in east Asian samples, a population that lacks admixture of Native American and European populations and shows little genetic substructure. This result argues against population stratification as an explanation for the finding in Latin American populations.
We estimated the difference in disease prevalence attributable to a risk factor with OR 5 1.20 (1.09-1.31), 26% frequency in Mexican Americans (as in the SIGMA control samples) and 2% in European Americans. Approximately 20% (9.2-29%) of the difference in prevalence could be explained by such a risk factor (Supplementary Methods).
Two population genetic features of the 5 SNP haplotype struck us as discordant. The haplotype sequence is highly divergent, with an estimated time to most recent common ancestor (TMRCA) of 799,000 years to a European haplotype (Supplementary Table 9 and Supplementary Note). This long precedes the 'out of Africa' bottleneck. And yet, the haplotype is not observed in Africa and is rare throughout Europe (Fig. 1d) .
This combination of age and geographical distribution could be consistent with admixture from Neanderthals into modern humans. Neither the published Neanderthal genome 14 nor the Denisova genome 15 contained the variants observed on the 5 SNP haplotype. However, an unpublished genome of a Neanderthal from Denisova Cave 16, 17 is homozygous across 5 kb for the 5 SNP haplotype at SLC16A11, including all four missense SNPs. Over a span of 73 kb this Neanderthal sequence is nearly identical to that of individuals from the 1000 Genomes Project who are homozygous for the 5 SNP haplotype (Supplementary Note).
Two lines of evidence indicate that the 5 SNP haplotype entered modern humans through archaic admixture. First, the Neanderthal sequence is more closely related to the extended 73 kb 5 SNP haplotype than to random non-risk haplotypes (mean TMRCA 5 250,000 years versus 677,000 years; Supplementary Tables 10 and 11 and Supplementary Note), forming a clade with the risk haplotype (Extended Data Fig. 6b ) with a coalescence time that post-dates the range of estimated split times between modern humans and Neanderthals 15, 18 . Second, the genetic length of the 73-kb haplotype is longer than would be expected if it had undergone recombination for ,9,000 generations since the split with Neanderthals (P 5 3.9 3 10
25
; Supplementary Note). These two features indicate that the 5 SNP haplotype is not only similar to the Neanderthal sequence, but was probably introduced into modern humans relatively recently through archaic admixture. We note that whereas this particular Neanderthal-derived haplotype is common in the Americas, Latin Americans have the same proportion of Neanderthal ancestry genome-wide as other Eurasian populations (,2%) 15 .
With an absence of multiple independently segregating functional mutations in the same gene, we lack formal genetic proof that SLC16A11 is the gene responsible for association to type 2 diabetes at 17p13.1. Nonetheless, as the associated haplotype encodes four missense SNPs in a single gene (Supplementary Table 12 ), we set out to begin characterizing the function of SLC16A11.
We examined the tissue distribution of SLC16A11 mRNA expression using Nanostring and ,55,000 curated microarray samples. In both data sets, we observed SLC16A11 expression in liver, salivary gland and thyroid (Extended Data Figs 7 and 8) . We used immunofluorescence to determine the subcellular localization of V5-tagged SLC16A11 introduced into HeLa cells. SLC16A11-V5 co-localizes with the endoplasmic reticulum membrane protein calnexin, but shows minimal overlap with plasma membrane, Golgi apparatus and mitochondria (Fig. 2a) . Distinct patterns were seen for other SLC16 family members, which are known to have diverse cellular functions 19 : SLC16A13-V5 localizes to the Golgi apparatus and SLC16A1-V5 appears at the plasma membrane 20 (Extended Data Fig. 9 and data not shown).
As SLC16 family members are solute carriers, we expressed SLC16A11 (or control proteins) in HeLa cells (which do not express SLC16A11 at Table 14 . Metabolite data shown are the combined results from three independent experiments, each of which included 12 biological replicates each for SLC16A11 and control.
LETTER RESEARCH appreciable levels) and profiled ,300 polar and lipid metabolites. Expression of SLC16A11 resulted in substantial increases in triacylglycerol (TAG) levels (P 5 7.6 3 10
212
), with smaller increases in intracellular diacylglycerols (P 5 7.8 3 10
23
) and decreases in lysophosphatidylcholine (P 5 2.0 3 10
), cholesterol ester (P 5 9.8 3 10
24
) and sphingomyelin (P 5 3.9 3 10
23
) lipids (Fig. 2b, c and Supplementary Tables  13 and 14) . As TAG synthesis takes place in the endoplasmic reticulum in the liver 21 , these results indicate that SLC16A11 may have a role in hepatic lipid metabolism. We note that serum levels of specific TAGs have been prospectively associated with future risk of type 2 diabetes 22 and accumulation of intracellular lipids has been implicated in insulin resistance in human populations 23, 24 . In summary, GWAS in Mexican and other Latin American samples identified a haplotype containing four missense SNPs, all in SLC16A11, that is much more common in individuals with Native American ancestry than in other populations. Each haplotype copy is associated with a ,20% increased risk of type 2 diabetes. With these properties, the haplotype would be expected to contribute to the higher burden of type 2 diabetes in Mexican and Latin American populations 25 . The haplotype derives from Neanderthal introgression, providing an example of Neanderthal admixture affecting physiology and disease susceptibility today. Our data suggest the hypothesis for future studies that SLC16A11 may influence diabetes risk through effects on lipid metabolism in the liver. Our results also indicate that genetic mapping in understudied populations can identify previously undiscovered aspects of disease pathophysiology 
METHODS SUMMARY
DNA samples were prepared using strict quality control procedures and genotyped using the Illumina HumanOmni2.5 array. Stringent sample and SNP quality (including ancestry) filters were applied on the resulting genotypes. After imputation 7, 8 , SNPs were quality filtered (MAF $1% and info score $0.6) and association testing was performed via LTSOFT 10 with type 2 diabetes status, BMI, and age modelling liability and adjusting for sex and top two principal components as fixed effect covariates. P values were corrected for genomic control (l GC 5 1.046). Odds ratios (ORs) are from logistic regression in PLINK 26 using BMI, age, sex, and top 2 principal components as covariates. Proportion of Native American ancestry was estimated using ADMIXTURE 27 (K 5 3) run including unadmixed individuals from several populations.
Odds ratios for young (#45 years) and older age of onset cases were calculated using logistic regression in each group compared to two randomly selected nonoverlapping sets of controls. Significance testing used a Z-score calculated from these odds ratios.
Population prevalence was modelled using odds ratio to approximate relative risk in a log-additive effect model 28 . Relative change in population prevalences is reported based on removing a locus with relative risk of 1.20 and the indicated frequency.
Gene expression analyses were performed on data collected using Nanostring and a compendium of publicly available Affymetrix U133 Plus 2.0 microarrays. The subcellular localization of SLC16A11-V5 and metabolic profiling studies were performed after expression of carboxy-terminus, V5-tagged SLC16A11 in HeLa cells. Metabolite values were normalized to the total metabolite signal obtained for each sample. Measurements were obtained in replicate from each of three independent experiments, with data combined after subtracting the mean of the logtransformed values. The Wilcoxon rank sum test was used to test for differences in individual metabolite levels in cells expressing SLC16A11 compared to controls; the Wilcoxon signed rank test was used to assess differences in lipid classes.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper. 
